A single-center, retrospective cohort study using ICIs as a first-line treatment for KRAS-mutant advanced NSCLC patients reported a median PFS of 16.2 months and a median OS of 31.3 months [66]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.